10074-G5: c-Myc Inhibitor for Cancer Research and Apoptosis Assays

Executive Summary: 10074-G5 is a small-molecule inhibitor targeting the c-Myc/Max dimerization interface, a key driver in multiple cancer types (García-Castillo et al., 2025). Quantitative in vitro studies demonstrate potent activity with IC50 values of 15.6 ± 1.5 μM in Daudi cells and 13.5 ± 2.1 μM in HL-60 cells (APExBIO). In vivo, intravenous dosing at 20 mg/kg for 10 days significantly suppresses tumor growth without affecting body weight. 10074-G5 is highly soluble in DMSO (≥37.9 mg/mL), but insoluble in water, and should be stored at -20°C. This article details the compound's mechanism, evidence base, and integration into cancer research workflows, clarifying common misconceptions and practical limitations.

Biological Rationale

c-Myc is a basic helix-loop-helix leucine zipper (bHLH-ZIP) transcription factor critical for cellular growth, metabolism, differentiation, and apoptosis (García-Castillo et al., 2025). Overexpression of c-Myc is frequently observed in prostate, pancreatic, lung, breast, and colon cancers, as well as B-cell lymphoma and leukemias. Elevated c-Myc levels often correlate with poor prognosis and aggressive tumor behavior. The c-Myc/Max heterodimer is required for transcriptional activation of genes involved in cell cycle progression and oncogenesis. Disruption of the c-Myc/Max interaction is a validated strategy for inhibiting oncogenic signaling in preclinical models. Targeting c-Myc is a key focus of contemporary anticancer drug development, particularly for tumors driven by the MYC/TERT/NFκB axis (García-Castillo et al., 2025).

Mechanism of Action of 10074-G5

10074-G5 is a small-molecule inhibitor designed to prevent c-Myc/Max dimerization (APExBIO). The c-Myc/Max complex binds E-box DNA sequences, promoting transcription of pro-proliferative and anti-apoptotic genes. 10074-G5 binds directly to the c-Myc bHLH-ZIP domain, blocking Max association and inhibiting DNA binding. At 10 μM, 10074-G5 effectively disrupts c-Myc/Max dimerization and reduces total c-Myc protein levels in cellular models. This inhibition triggers cell cycle arrest, apoptosis, tumor vascular degeneration, and tumor regression in relevant preclinical systems. The specificity of 10074-G5 for the c-Myc/Max interface underpins its utility in dissecting oncogenic transcription factor pathways.

Evidence & Benchmarks

• 10074-G5 exhibits an IC50 of 15.6 ± 1.5 μM against Daudi cells (lymphoma line) in proliferation assays (APExBIO).
• IC50 of 13.5 ± 2.1 μM is reported for HL-60 cells (myeloid leukemia) under identical conditions (APExBIO).
• At 10 μM, 10074-G5 reduces c-Myc/Max dimerization and total c-Myc protein levels in vitro (García-Castillo et al., 2025).
• In vivo, intravenous administration at 20 mg/kg daily for 10 days significantly suppresses Daudi xenograft tumor growth with no effect on animal body weight (APExBIO).
• 10074-G5 is highly soluble in DMSO (≥37.9 mg/mL) and ethanol (≥3.53 mg/mL with ultrasound), but insoluble in water (APExBIO).
• Purity is typically ≥98% by HPLC, supporting reliable biological interpretation (APExBIO).
• c-Myc inhibition reverses epithelial-to-mesenchymal transition and aggressive features in esophageal adenocarcinoma models driven by the MYC/TERT/NFκB axis (García-Castillo et al., 2025).

For an in-depth, scenario-based application of 10074-G5 in advanced cancer workflows, see this practical methods article, which focuses on protocol optimization and real-world assay troubleshooting. Our current article provides expanded mechanistic context, quantitative benchmarks, and clarifies limitations not covered in the protocol-focused resource. A broader review of c-Myc inhibitor strategies and translational outlook is available in this mechanistic analysis, whereas the present article emphasizes direct evidence and actionable workflow parameters.

Applications, Limits & Misconceptions

10074-G5 is used to dissect the c-Myc signaling pathway in cancer models, supporting apoptosis assays, cell cycle arrest studies, and tumor regression experiments. Its quantitative performance metrics enable rigorous evaluation of c-Myc as an oncogenic driver and therapeutic target. The compound is suitable for use in both hematological and solid tumor models where c-Myc overexpression is implicated. 10074-G5 is also valuable for studying transcription factor inhibition and the molecular consequences of disrupting oncogenic protein-protein interactions. However, its utility is limited by solubility constraints (insoluble in water) and moderate potency (μM-range IC50). It is not recommended for long-term solution storage or for in vivo use outside validated dosing regimens.

Common Pitfalls or Misconceptions

• 10074-G5 does not inhibit c-Myc-driven processes in cells lacking c-Myc/Max dimerization or with unrelated oncogenic drivers.
• It is ineffective in aqueous (water-based) systems due to insolubility; use DMSO or ethanol as solvents, following recommended concentrations.
• The compound is not a pan-transcription factor inhibitor; its specificity is for the c-Myc/Max interface.
• Long-term storage of prepared solutions is discouraged; only store the solid at -20°C for maximum stability.
• Apparent cytotoxicity at very high concentrations may reflect off-target effects or solvent toxicity, not specific c-Myc inhibition.

Workflow Integration & Parameters

10074-G5 is supplied as a crystalline solid (molecular weight: 332.3; C18H12N4O3; N-[1,1'-biphenyl]-2-yl-7-nitro-2,1,3-benzoxadiazol-4-amine) by APExBIO. Reconstitute at ≥37.9 mg/mL in DMSO or ≥3.53 mg/mL in ethanol with sonication. Avoid water as a solvent. Store at -20°C as a dry solid; freshly prepare working solutions prior to each experiment. For cell-based assays, use concentrations of 10–20 μM, adjusting for cell type and endpoint (e.g., apoptosis, proliferation, or cell cycle arrest). In vivo, validated dosing is 20 mg/kg intravenous, daily x10 days, in Daudi xenograft models. For further guidance on cell viability, proliferation, and cytotoxicity assay setup, see this evidence-driven workflow article, which this review extends by providing updated quantitative benchmarks and mechanistic detail.

Conclusion & Outlook

10074-G5 is a robust tool for mechanistic and translational cancer research, enabling targeted modulation of the c-Myc/Max dimerization interface. Its reproducible activity in apoptosis, cell cycle, and tumor regression studies is supported by quantitative evidence in both in vitro and in vivo models. The product's specificity, solubility profile, and validated dosing parameters make it suitable for a wide range of experimental systems where c-Myc is implicated as a driver of oncogenesis. As research advances in the MYC/TERT/NFκB axis, 10074-G5 will remain an essential compound for dissecting transcription factor signaling and developing novel anticancer strategies.

For full technical details, ordering, and documentation, visit the 10074-G5 product page from APExBIO.